Pharmacovigilance / Cancer

(A-229) A,B,Cs of ADCs (Antibody–Drug Conjugates) Post-Marketing Pharmacoepidemiology Planning

(A-227) Adverse Drug Events Associated with Pembrolizumab In Pediatric Oncology: Analysis of Global and Local Individual Case Safety Reports

(A-228) Adverse Pulmonary Reactions Associated with Proteasome Inhibitors in Multiple Myeloma: A Disproportionality Analysis of the FDA Adverse Event Reporting System

(A-225) How are RWE/RWD used in pharmacovigilance for the development of oncologic products in early stages?

(A-230) Medication Errors in Breast Cancer Treatment and Pharmacist-Led Interventions at the largest referral hospital in Kenya.

(B-246) Safety of Immune Checkpoint Inhibitors: A Systematic Review of Disproportionality Analysis Studies

(A-224) Signal Detection of Dementia Associated with Alkylating Agents: Using the World Health Organization Pharmacovigilance Database

(A-226) Target Fishing and Drug Repurposing for Esophageal Adenocarcinoma: An Integrated Bioinformatic and Pharmacovigilance Approach